Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

about

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

Item

http://www.wikidata.org/entity/Q49931866

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.

@en

Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.

@nl

type

Item

label

Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.

@en

Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.

@nl

prefLabel

Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.

@en

Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.

@nl

P1476

Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.

@en

P2093

Andrew Spencer

http://www.w3.org/2001/XMLSchema#string

Douglas Joshua

http://www.w3.org/2001/XMLSchema#string

Karim S Iskander

http://www.w3.org/2001/XMLSchema#string

Shibao Feng

http://www.w3.org/2001/XMLSchema#string

Wee-Joo Chng

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2016

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Association of response endpoints with survival outcomes in multiple myeloma.

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.

Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.

P304

1-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1376743

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Goldschmidt

Meletios A. Dimopoulos

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28937327

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone